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Progress in adjuvant treatment of melanoma patients
Piotr Rutkowski1, Wojciech M. Wysocki2, Tomasz Świtaj1, Arkadiusz Jeziorski3
Surgery is therapy of choice in melanoma patients. However, prognosis of patients at stage IIC–IV even after radical 
resection is very heterogenous and related to high risk of disease relapse. Positive results of clinical trials indicate 
that in the nearest future systemic adjuvant therapy in high risk melanomas will become the standard of care. New 
treatment modalities, both molecular targeted therapy with BRAF+MEK inhibitors dabrafenib with trametinib and 
immunotherapy anti-PD-1 with nivolumab or pembrolizumab have been approved in US and EU.
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Surgery is therapy of choice in melanoma patients, ho-
wever, prognosis in patients at stage IIC–IV melanomas even 
after radical resection is very heterogenous and to a large 
extent related to high risk of disease relapse [1–5].
Adjuvant therapy after surgical treatment is currently 
used in specific cases, although studies indicate that syste-
mic adjuvant therapy in the discussed group of melanoma 
patients will become the standard of care. New systemic 
therapies have already been registered in the United States 
and the European Union. In view of the combination of 
surgery and conservative treatment, the basic and binding 
principle should be the management by multi-specialist 
teams, whose members have experience in the diagnosis 
and treatment of patients with melanoma at locoregional 
and generalised settings.
Adjuvant radiotherapy
In individual cases, after surgery in patients with high 
risk melanoma, adjuvant radiotherapy (RTH) is possible — 
the dosing regiment includes hypofractionation using 3–8 
Gy/fraction or conventional fractionation depending on 
the location. The indications for adjuvant RTH after primary 
tumour excision may include:
 — diagnosis of desmoplastic melanoma excised with nar-
row margins,
 — the presence of ‘positive’ surgical margins (especially 
after the local recurrence resection) while no surgical 
radicalisation is possible,
 — the presence of satellite lesions,
 — enhanced neurotropism, 
 — location in the head and neck region (caution: RTH as an 
exclusive treatment method can be used with extensive 
LMM lesions).
In case of local resection and lymphadenectomy due 
to metastases at regional lymph nodes, the indications for 
complementary RTH may be:
 — the presence of extracapsular node invasion,
 — spread to ≥ 4 lymph nodes (stage IIIC)
 — metastasis diameter > 3 cm,
 — metastases in the neck lymph nodes (from 2 metastatic 
lymph nodes or at a minimum metastasis size of 2 cm),
 — relapse after prior resection [1, 2, 4, 6].
The results of the only completed randomized clinical 
trial , which evaluated the value of adjuvant radiotherapy 
(48 Gy in 20 fractions) after lymphadenectomy in case of 
high risk of relapse, confirmed the improvement of local 
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control after irradiation, but at the same time no effect on 
overall survival was observed, with an increase in frequen-
cy of late locoregional complications and deterioration of 
patients’ quality of life. Therefore, the conclusions from this 
study indicate that the use of adjuvant radiotherapy should 
be limited [7, 8]. It should also be emphasized that there 
are no indications of an adjuvant RHT after the completion 
lymphadenectomy following a positive sentinel lymph node 
biopsy (CLND).
Systemic adjuvant therapy
At present, there are no Polish and European recom-
mendations for routine systemic adjuvant therapy in clinical 
practice at patients after the radical resection of primary 
lesions and lymphadenectomy, and adjuvant radiotherapy 
can only be considered in the specific situations described 
above. The results of recently published clinical studies in-
dicate an improvement in survival, both from the use in 
adjuvant therapy the immunotherapy with the immune 
checkpoint inhibitors and from the combination therapy 
with BRAF and MEK inhibitors, and it can be expected that 
such treatment will become a standard of care in the nearest 
future, as it happened in US [1–4].
Interferon
For many years, apart from interferon (IFN), no other 
agents has been effective in the treatment of high risk skin 
melanomas. Interferon (mainly IFN-a-2b, used only in mono-
therapy) in the adjuvant therapy of melanoma patients (for 
a selected group) in most studies resulted in prolongation 
(in a repetitive manner) of relapse-free survival (RFS) (Tab. I) 
[4, 9–13]. The evidence of improved overall survival (OS) as 
a result of the use of IFN is much weaker and more contro-
versial. In 10 out of 17 evaluated studies an improvement 
in RFS was observed, with the latest meta-analyses showing 
a reduction in the risk of relapse by 17–18% [relative risk 
(HR hazard ratio) 0.82–0.83; p < 0.0001] when using IFN in 
adjuvant therapy. The evidence for OS improvement comes 
mainly from meta-analyses and it is reflected in the impro-
vement of OS by about 3% over 5 years in the whole group 
of patients. The use of adjuvant IFN treatment in all high-
-risk melanoma patients is therefore not justified (especially 
considering its high toxicity) and remains optional only for 
selected patients. Interferon a-2b (IFN a-2b) in high doses 
was registered in the United States and the European Union 
for IIB–III stage melanomas on the basis of a positive result 
of one of three studies of the Eastern Cooperative Oncology 
Group (ECOG) — ECOG 1684, while this drug was registered 
in low doses in Europe for II stage patients. The basis for regi-
stration was a significant increase in the overall survival time 
during the period of about 7 years of observation, which, 
however, after a longer period (12 years) was not confirmed. 
The results of meta-analyses indicate that the basic group of 
patients benefiting from IFN adjuvant therapy are those with 
ulcerated primary melanoma, especially in the subgroup of 
patients with clinically undetectable metastases in the sen-
tinel node (formerly known as micro-metastases), and not 
with clinically diagnosed metastases found in swollen (pal-
pable) lymph nodes (formerly known as macro-metastases) 
[11, 12]. Results of a study by the European Organisation for 
Research and Treatment of Cancer 18081 (EORTC 18081) are 
currently expected; its aim is to assess the use of pegylated 
IFN in the treatment of patients after primary ulcerated cuta-
neous melanoma resection without metastases to regional 
lymph nodes (interrupted study recruitment). The most 
common side effects are parainfluenza symptoms, fever, 
weakness, neutropenia, hepatotoxicity and depression. Part 
of the IFN toxicity profile changes during therapy. Along 
the course of treatment, parainfluenza symptoms decrease, 
while other reported side effects remain the same or even 
increase with the duration of treatment (mainly fatigue, 
anorexia, symptoms of depression/anxiety).
Immunotherapy with immune checkpoint 
inhibitors
In 2015, preliminary results of a study on the use of 
adjuvant treatment with anti-CTLA-4 antibodies (ipilimu-
mab) after lymphadenectomy due to metastases to regional 
lymph nodes (stage III) were published. The study inclu-
ded 951 patients who were randomly allocated to the ipi-
limumab high-dose group at 10 mg/kg body weight every 
3 weeks and then every 3 months up to 3 years (n = 476) or 
placebo (n = 476). With a median of the observation time 
being 2.7 years, 234 events were reported with reference 
to RFS in ipilimumab-treated group compared to 294 for 
placebo-treated group; the median RFS was 26.1 months 
compared to 17.1 months (p = 0.0013), respectively. The 
improvement of RFS referred to patients with both ma-
cro- and micro-metastases (definitions according to then 
valid 7th revision of TNM staging system) to lymph nodes; 
the result of adjuvant therapy was more important at the 
ulceration of the primary lesion. In the ipilimumab-treated 
group, 54% of patients had side effects with 3–4 toxicity le-
vels compared to 25% in the placebo-treated group. Due to 
complications connected with ipilimumab administration, 
5 patients (1%) died. Side effects led to permanent disconti-
nuation of treatment in 52% of patients entering ipilimumab 
treatment [14]. The results of this study, presented in 2016 
with a median follow-up time at 5.3 years, show a significant 
improvement in the use of ipilimumab adjuvant therapy in 
high doses for both RFS as well as distant metastasis free 
survival and OS. The percentage of 5-year OS in the group 
receiving ipilimumab was 65.4% compared to 54.4% in the 
group receiving placebo (hazard ratio for death 0.72, 95.1% 
CI 0.58–0.88; p = 0.001) [15]. Preliminary results of a subse-
quent E1609 study showed similar efficacy of a lower dose 
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of ipilimumab (3 mg/kg) with less toxicity. The EORTC 18071 
study has led to the registration of ipilimumab in the United 
States as an adjuvant therapy for melanoma patients after 
lymphadenectomy due to metastases to regional lymph 
nodes, however, its practical application is limited due to 
its high toxicity and more favourable test results with an-
ti-PD-1 antibodies (nivolumab and pembrolizumab) and 
kinase inhibitors.
Nivolumab in a randomized clinical trial (CheckMate 
238) in patients after resection of metastases at stage IIIB, IIIC 
and IV showed a 10% improvement in relapse-free survival 
if compared with ipilimumab at a lower toxicity (18-month 
RFS: 65% vs 53%). This is the only study where patients 
after the resection of distant metastases were also inclu-
ded. The improvement of distant metastases free survival 
(DMFS) was also demonstrated (HR 0.73). Adverse events 
associated with treatment at stage III or IV were reported 
Table I. Summary of the results of the most important clinical trials on adjuvant therapy with interferon (INF). Bold typeface distinguishes the studies 
where a significant benefit was obtained from INF therapy [acc. to 13]
Study Study period/
INF type
Melanoma 
stage
RFS OS
Very low doses of interferon, 0.5–1 million IU
EORTC 18871/DKG-80 1 year/
INF-α-2b
IIB, III p = 0.02 p = 0.18
Low doses of interferon, 3 million IU
Austria 1 year/
INF-α-2a
IIB, III p = 0.02 p = 0.6
France 18 months/
INF-α-2a
IIB, III Benefit
(p = 0.035)
p = 0.06
WHO-16 3 years/
INF-α-2a
III p = 0.5 p = 0.7
E1690 2 years/
INF-α-2b
IIB, III p = 0.17 p = 0.81
Scotland 6 months/
INF-α-2b
IIB, III p = 0.051 p = 0.4
Germany 2 years/
INF-α-2a
III p = 0.0045 p = 0.018
UKCCCR 2 years/
INF-α-2a
IIB, III p = 0.3 p = 0.6
Intermediate doses of interferon, 10 million IU
EORTC 18952 13 months/
INF-α-2b
IIB, III Benefit only in subgroup IIB No benefit
25 months/
INF-α-2b
IIB, III Benefit only in the IIB subgroup or 
in the group of patients with micro-
metastases after a positive sentinel 
lymph node biopsy
No benefit
High doses of interferon, 20 million IU/m2 vs observation
E1684 52 weeks/
INF-α-2b
IIB, III p = 0.02 p = 0.01
E1690 52 weeks/
INF-α-2b
IIB, III No benefit No benefit
NCCTG 83707 3 months/
INF-α-2a
IIA, IIB, III p = 0.24 p = 0.53
Sunbelt Melanoma Trial 52 weeks/
INF-α-2b
IIIA No benefit No benefit
High doses of interferon, 20 million IU/m2 vs vaccine
E1694 96 weeks/
INF-α-2b vs GMK vaccine
IIB, III p = 0.0015 p = 0.009
Long-term administration of pegylated interferon vs observation
EORTC 18991 p = 0.01; improvement by 6.7% p = 0.78
RFS — relapse-free survival; OS — overall survival
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Table II. Sum
m
ary of recent clinical studies on adjuvant therapy after m
elanom
a resection w
ith a high relapse risk
EO
RTC 18071
Ipilim
um
ab vs placebo
BRIM
-8
Vem
urafenib vs placebo
CO
M
BI-AD
D
abrafenib + tram
etinib vs placebo
Checkm
ate 238
IPI vs N
IVO
EO
RTC 1325/Keynote 054
Pem
brolizum
ab vs placebo
Author
Eggerm
ont 2015 Eggerm
ont 2016
Lew
is 2017
Long 2017
W
eber 2017
Eggerm
ont 2018
Population
IIIA (> 1 m
m
), IIIB, IIIC
IIC, IIIA, IIIB, IIIC
IIIA (> 1 m
m
), IIIB, IIIC
IIIB, IIIC, IV
IIIA (> 1 m
m
), IIIB, IIIC
BRAF m
utation
?
100%
100%
41%
 / 43%
RFS
41%
 vs 30%
 (5 years)
82%
 vs 63%
 (12 m
onths) 
62%
 vs 53%
 (24 m
onths)  
79%
 vs 58%
 (12 m
onths)  
46%
 vs 47%
 (24 m
onths) IIIC
84%
 vs 66%
 (12 m
onths)  
72%
 vs 56%
 (24 m
onths) IIC–IIIB
67%
 vs 44%
 (2 years) 
H
R = 0.47
58%
 vs 39%
 (3 years)
66%
 vs 53%
 (18 m
onths) 
62,6%
 vs 50.2%
 (24 m
onths)  
H
R 0.66 vs H
R 0.65
H
R 0.57; difference after 18 m
onths 
18.2%
: 71.4%
 vs 53.2%
O
S
65%
 vs 54%
 (5 years) 
HR = 0.72
N
DA
91%
 vs 83%
 (2 years) 
86%
 vs 77%
 (3 years)  
H
R = 0.57
N
DA
O
S —
 overall survival, RFS —
 relapse-free survival, N
DA —
 no data available
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in 14.4% of patients receiving nivolumab as compared to 
45.9% in the ipilimumab-treated group [16]. Updated data 
from 2018, with a longer period of observation, confirm the 
beneficial effect of nivolumab in adjuvant therapy for one 
year, regardless of the PD-L1 expression status and BRAF 
mutation with respect to RFS (HR 0.66) and DMFS (HR 0.76) 
[17]. Nivolumab is currently registered for adjuvant therapy 
in the United States and the European Union.
Preliminary results of Keynote-054/EORTC 1325 trial in 
1019 patients also indicate a reduction in the risk of relapse 
(HR for RFS 0.57) and DMFS using pembrolizumab adjuvant 
therapy for one year compared to placebo in the group of 
patients with resection stage III with a higher risk (IIIA with 
micro-metastasis size > 1 mm, IIIB and IIIC) [18]. A study 
comparing the use of nivolumab in adjuvant therapy with 
a combination of nivolumab and ipilimumab is currently 
under way (CheckMate 915).
Molecularly targeted treatment
Adjuvant therapy using dabrafenib with trametinib in 
patients with high risk BRAF mutation level III showed im-
provement in RFS (HR 0.47), DMFS (HR 0.51; 91% vs 70% 
after 1 year, 77% vs 60% after 2 years and 71% vs 57% after 
3 years) and OS (HR 0.57) compared to placebo. In this stu-
dy (COMBI-AD) dabrafenib with tramethinib were used for 
1 year compared to placebo (stage IIIA with a metastasis 
di meter > 1 mm, IIIB/C) [19]. This study is the only one apart 
from the study with ipilimumab discussed above that has 
shown a significant improvement in overall survival rate. The 
safety profile of dabrafenib with tramethinib was consistent 
with that observed in the study, which included patients 
with melanoma at the IV stage of development. Dabrafenib 
with trametinib are currently approved for adjuvant therapy 
in the United States and the European Union. The formally 
‘positive’ clinical trial BRIM-8 [20] also included the use of 
vemurafenib monotherapy in adjuvant therapy for one year 
as compared to placebo in patients with melanoma after 
stage IIC–III resection (the only study to date covering pa-
tients at stage II). The median disease-free survival (DFS) was 
23.1 months in the vemurafenib-treated group compared 
to 15.4 months in the placebo group (HR 0.8; p = 0.026), but 
this effect was limited only to the IIC–IIIA–IIIB subgroup, 
and was not visible to more advanced patients at stage IIIC. 
At the same time, it is known from the current practice at 
patients with metastatic melanoma that monotherapy with 
BRAF inhibitors is not optimal if compared to the combined 
treatment of patients with the presence of BRAF mutations 
with BRAF and MEK inhibitors.
Summary
The results of systemic adjuvant therapy with immuno-
therapy after high-risk melanoma resection are summarised 
in Table II. Other immunotherapy methods (e.g. interleu-
kin-2), vaccines or drugs with cytotoxic effects have no 
practical use in adjuvant postoperative therapy [1, 4, 5, 21].
In summary, adjuvant therapy with anti-PD-1 immu-
notherapy (ninolumab or pembrolizumab) or combined 
treatment with BRAF and MEK inhibitors (dabrafenib with 
tramethinib for populations with BRAF mutations) is beco-
ming a new standard of care after melanoma resection with 
high risk of relapse (resection stages IIIA–IV) according to 
American and Polish recommendations [2, 4, 22]. This, in 
turn, means that the treatment of all patients with mela-
nomas with stages from IIIA to IV should be discussed at 
multi-specialist team meetings in order to ensure optimal, 
modern and as effective a treatment as possible. In addition, 
it is important to ensure that high risk melanoma patients 
are included in prospective clinical trials of new adjuvant 
therapy where possible.
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